Pulmovant
Pulmovant is seeking a highly skilled and experienced Head of Analytical Development to lead the analytical function, reporting to the Executive Director of Pharmaceutical Development. This role is accountable for the integrated analytical control strategy spanning the drug substance, micronized active pharmaceutical ingredient (API), and dry powder inhaler (DPI) drug product. The position involves leading analytical teams, ensuring regulatory readiness for NDA preparation and pre-approval inspections, and collaborating with cross-functional teams and external partners.
Pulmovant is a clinical-stage biopharmaceutical company singularly focused on developing innovative inhaled therapies for pulmonary diseases, including pulmonary hypertension. The company's lead candidate, mosliciguat, is a potentially first-in-class once-daily inhaled treatment with a differentiated soluble guanylate cyclase (sGC) activation mechanism. Pulmovant is advancing mosliciguat through clinical trials with the goal of transforming the treatment paradigm for patients with pulmonary diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Pulmovant.
Pulmovant completes enrollment for PH-ILD treatment trial
1 month ago
Analytical Development Lead
ShopZoi
Associate Director, Analytical Development
Avalyn Pharma
Principal Analytical QA Specialist, Drug Substance
Loyal
Sr. Principal Scientist/Sr. Director, Regulatory Affairs
MSD
Director, Analytical Development
Sarepta Therapeutics
AD/Director of Analytical Development
nuvationbio